Glimstin M 2 Tablet PR is a combination oral antihyperglycemic agent containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby improving glycemic control. Metformin, a biguanide, primarily reduces hepatic glucose production and enhances peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. This dual mechanism addresses both insulin deficiency and insulin resistance, making Glimstin M 2 Tablet PR effective for patients inadequately controlled by diet, exercise, and monotherapy. The tablet is designed for prolonged release, ensuring sustained plasma concentration and improved patient compliance. It is recommended to be administered with meals to minimize gastrointestinal side effects commonly associated with Metformin. Glimstin M 2 Tablet PR should be used under medical supervision, with periodic monitoring of blood glucose levels, renal function, and potential adverse effects such as hypoglycemia, lactic acidosis, and gastrointestinal disturbances. Dose adjustments may be necessary based on therapeutic response and tolerability. This combination therapy offers a comprehensive approach to glycemic management in type 2 diabetes, aiming to reduce the risk of diabetes-related complications and improve overall metabolic control.

Dosage & How to Use